Post-earnings recap
Reported
Mon, May 4, 2026
EPS actual
$0.05
EPS est.
$-0.30
EPS surprise
+116.78%
1-day move
+1.79%
Travere Therapeutics reported a surprising positive EPS, beating expectations significantly. However, there was no revenue reported against the consensus estimate. The stock reacted positively, rising by 1.79%, likely reflecting investor optimism about the unexpected earnings performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.05 | $-0.05 | +116.78% |
| Revenue | — | $136M | — |
No transcript is on record, and the analysis is based on numerical results only.
Travere Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases. With a market cap of $4 billion, it plays a crucial role in addressing unmet medical needs in the health care sector.
Last quarter
In Q4 2025, Travere reported an EPS of $0.37, significantly exceeding expectations. The stock reacted positively, gaining 5.13% the following day.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+253.84%
Avg 1-day reaction
+1.31%
Analysts are cautiously optimistic about Travere's upcoming earnings, expecting a small loss in EPS but solid revenue figures.
Bull case
If Travere can beat the EPS estimate and show strong revenue growth, it could signal a turnaround in profitability and boost investor confidence.
Bear case
Conversely, if the company misses on both EPS and revenue, it may raise concerns about its financial health and future growth prospects.
Key metrics to watch
EPS
-$0.05Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.
Revenue
$136MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the company achieve revenue of at least $136 million?
Meeting or exceeding this revenue target will indicate strong demand for Travere's products and could positively influence stock performance.
Q2
What is the outlook for EPS moving forward?
Guidance on future earnings will be critical for assessing the company's path to profitability and investor sentiment.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating Travere's ability to leverage recent product developments, which could drive higher-than-expected revenue.
Supporting evidence
The company's recent earnings surprises indicate a potential for continued strong performance.
Options pricing suggests a higher volatility expectation, which may reflect insider confidence in upcoming results.
Key risk
If revenue exceeds $162 million, it could invalidate the cautious consensus and shift investor sentiment positively.
Pre-commit to what would confirm each case.
The market is closely watching Travere's ability to balance growth with profitability, especially after recent strong earnings surprises.
Bull confirmed if
An EPS of $0.10 or better would confirm the bull case, showcasing improved cost management and revenue generation.
Bear confirmed if
An EPS loss greater than $0.23 would confirm the bear case, raising concerns about the company's financial stability.
What the market is pricing for the move.
Implied Move
±10.14%
Historical Avg
±2.0%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±10.4% while TVTX has averaged ±2.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
106.6%
Smart-money positioning from the most recent 13F filings.
Institutional
115.16%
of float
Insider
0.69%
of float
Holders
437
institutions
Top Holders· as of Jun 2026
Jupiter Topco LLC
11,324,191 sh · $605.2M
12.01%
100.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Travere beats expectations, history suggests a potential stock increase of around 0.52%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A significant miss could lead to a decline, with history suggesting an average drop of around 4.63%.
The lines on the call that would change the story.
Blackrock Inc.
8,020,663 sh · $428.6M
8.51%
2.9%
FMR, LLC
7,096,614 sh · $379.2M
7.53%
-35.3%
Bank of America Corporation
4,568,341 sh · $244.1M
4.85%
239.6%
State Street Corporation
4,256,224 sh · $227.5M
4.52%
-14.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.